risedronate sodium NDC 47335-928

NDC codes

FDA NDC Directory

Product NDC (as listed)47335-928Labeler and product segments. Claims need a package NDC.

Product NDC at billing width47335-0928Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
47335-928-60	47335092860	1 BLISTER PACK in 1 CARTON (47335-928-60) / 1 TABLET, FILM COATED in 1 BLISTER PACKMarketed from Jun 11, 2014
47335-928-67	47335092867	3 BLISTER PACK in 1 CARTON (47335-928-67) / 1 TABLET, FILM COATED in 1 BLISTER PACKMarketed from Jun 11, 2014

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): risedronate sodium
Generic name (nonproprietary): risedronate sodium
Active ingredients: Risedronate sodium hemi-pentahydrate — 150 mg/1
Dosage form: Tablet, Film coated
Route: Oral
Labeler: Sun Pharmaceutical Industries, Inc.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 090886
Marketing start: Jun 11, 2014
Listing expires: Dec 31, 2027
Other FDA classes: Diphosphonates (Chemical structure)
Identifiers: Product ID 47335-928_a9910c38-e099-4f8a-a7e9-a88623be2032SPL ID a9910c38-e099-4f8a-a7e9-a88623be2032SPL set ID e0b5f0ed-ff40-4f0d-bb86-81a7ace9f339RxCUI 905024, 905028, 905032, 905041, 905083, 905092, 905100UNII HU2YAQ274OUPC 0347335727982
Pharmacologic class: Bisphosphonate

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N447335092860 followed by a unit qualifier and the quantity

Package 47335-0928-60. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Feb 17, 2026.

Indications (excerpt from the label)

Risedronate sodium is a bisphosphonate indicated for: Treatment and prevention of postmenopausal osteoporosis ( 1.1 ) Treatment to increase bone mass in men with osteoporosis ( 1.2 ) Treatment and prevention of glucocorticoid-induced osteoporosis ( 1.3 ) Treatment of Paget's disease ( 1.4 ) Limitations of Use Optimal duration of use has not been determined. For patients at low-risk for fracture, consider drug discontinuation after 3 to 5 years of use. ( 1.5 ) 1.1 Postmenopausal Osteoporosis Risedronate sodium tablets are indicated for the treatment and prevention of osteoporosis in postmenopausal women. In postmenopausal women with osteoporosis, risedronate sodium tablets reduce the incidenc…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 090886

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 090886
Product	Strength	Form · route	Labeler	Product NDC
risedronate sodium	Risedronate sodium hemi-pentahydrate 35 mg/1	Tablet, Film coatedOral	Sun Pharmaceutical Industries, Inc.	47335-668
risedronate sodium	Risedronate sodium hemi-pentahydrate 5 mg/1	Tablet, Film coatedOral	Sun Pharmaceutical Industries, Inc.	47335-666
risedronate sodium	Risedronate sodium hemi-pentahydrate 30 mg/1	Tablet, Film coatedOral	Sun Pharmaceutical Industries, Inc.	47335-667
risedronate sodium	Risedronate sodium hemi-pentahydrate 75 mg/1	Tablet, Film coatedOral	Sun Pharmaceutical Industries, Inc.	47335-727